Free Daily Podcast Summary
JACC Global: Daily Summaries Delivered
by American College of Cardiology
Explore cardiovascular science from a global perspective with JACC Global. This podcast highlights original research, regional innovations, and urgent challenges in heart health across diverse healthcare settings worldwide.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 5 days ago33 min
Is “Normal” Hemoglobin Really Normal in Heart Failure? | JACC Baran
Hosts Mitsuaki Sawano, MD, and Satoshi Shoji, MD, welcome Misato Chimura, MD, PhD (University of Glasgow) to discuss her ESC SimPub paper in JACC, “Low-normal hemoglobin concentrations and clinical outcomes in heart failure.” Using individual participant-level data from 11 randomized trials including 42,213 patients across the full LVEF spectrum, the study examined the continuous relationship between hemoglobin and clinical outcomes. Risk was lowest around 14 g/dL in women and 15 g/dL in men, while even patients just above the WHO anemia threshold had higher event rates. The episode explores why “normal” may not always mean low risk in heart failure, the role of iron deficiency, how these findings should and should not influence clinical practice, and the research environment behind the study at the University of Glasgow.
- 1 weeks ago43 min
BRIDGING the Lipid Management Gap After ACS: ESC Late-Breaker | JACC Baran
Hosts Mitsuaki Sawano, MD, and Shun Kohsaka, MD, welcome Kazuma Ohyama, MD, PhD (Tohoku University) to discuss the BRIDGE trial, Protocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome. In this 10-center cluster-randomized trial, hospitals were assigned to either protocol-based or standard lipid management after emergency PCI for ACS. Rather than simply reminding clinicians to intensify therapy, the intervention specified what treatment to initiate, when to reassess LDL-C, when to escalate therapy, and who was responsible for each step. At 6 months, LDL-C
- 2 weeks ago36 min
ESC 2026 Special: JACC SimPub Papers You Should Know | JACC Baran
Hosts Mitsuaki Sawano, MD, Takeshi Kitai, MD, PhD, Kentaro Ejiri, MD, PhD, and Satoshi Shoji, MD, PhD, highlight three JACC papers presented at ESC 2026 and simultaneously published with the meeting. Dr. Kitai discusses new HELIOS-B insights on whether the benefits of vutrisiran in transthyretin amyloidosis with cardiomyopathy are maintained among patients already receiving tafamidis. Dr. Ejiri reviews a nationwide Swedish study of nearly 500,000 heart failure hospitalizations examining how cold spells, heat waves, and non-optimal temperatures influence short-term HF risk, including the different timing of risk after rising versus falling temperatures. Dr. Shoji explores how lepodisiran, an extended-duration siRNA targeting lipoprotein(a), markedly reduces oxidized phospholipids carried by Lp(a), providing further insight into the mechanisms linking Lp(a) with cardiovascular risk. The team discusses what these findings add to current evidence, how they may translate to clinical practice in Japan, and the key questions that remain.
- 3 weeks ago47 min
The Lancet: OPTIMA-AF, Is 1 Month Enough After PCI? | JACC Baran
Hosts Mitsuaki Sawano, MD, Shun Kohsaka, MD, Nobuhiro Ikemura, MD, and Satoshi Shoji, MD, welcome Yohei Sotomi, MD, PhD (The University of Osaka), and Ken Kozuma, MD, PhD (Teikyo University) for a special episode made possible through the JACC–Lancet partnership to discuss the OPTIMA-AF trial, published in The Lancet. In this investigator-initiated, multicenter randomized trial of 1,079 patients with atrial fibrillation undergoing PCI, 1 month of DOAC plus a P2Y12 inhibitor followed by DOAC monotherapy was compared with 12 months of dual antithrombotic therapy. The 1-month strategy met the prespecified noninferiority criterion for death or thromboembolic events and reduced major or clinically relevant non-major bleeding from 8.8% to 4.5%. The episode explores whether antithrombotic therapy after PCI can safely be shortened, how intracoronary imaging and contemporary PCI may influence this balance, and how the findings should be interpreted in clinical practice. Drs. Sotomi and Kozuma also take us behind the scenes of OPTIMA-AF, from an ambitious idea born through a research competition among Osaka University-affiliated hospitals, through COVID-related enrollment challenges and a prolonged recruitment period, to an initial rejection, appeal, extensive revision, and eventual publication in The Lancet.
- Aug 18, 202638 min
HFpEF: Why Earlier May Be Better | JACC Baran
Hosts Mitsuaki Sawano, MD, Nobuhiro Ikemura, MD, and Satoshi Shoji, MD welcome Shunichi Doi, MD (St. Marianna University School of Medicine) to discuss his JACC: Heart Failure study, Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II. In this prespecified subanalysis of the REDUCE LAP-HF II trial, 522 patients with HFpEF or HFmrEF were categorized by time since heart failure diagnosis (3 years). Longer disease duration was associated with progressive left and right ventricular dysfunction, biatrial remodeling, worsening resting and exercise hemodynamics, and higher rates of heart failure events. In contrast, patients with more recent diagnoses often had normal resting filling pressures with congestion evident only during exercise, suggesting that early HFpEF may be missed by conventional evaluation. The discussion explores whether HFpEF phenotypes represent distinct disease entities or sequential stages of progression, why exercise hemodynamic testing may be critical for early diagnosis, and how identifying HFpEF before advanced remodeling develops may open opportunities for earlier intervention.
- Aug 11, 202635 min
Post-PCI Hematoma: What IVUS Tells Us | JACC Baran
Percutaneous coronary intervention (PCI) is safer than ever, yet coronary hematoma remains an underrecognized cause of early ischemic complications. In this episode, Host Mitsuaki Sawano, MD welcome Takunori Tsukui, MD and Akiko Maehara, MD to discuss their JACC: Cardiovascular Interventions study comparing 22 event-causing hematomas with 80 event-free hematomas identified from more than 3,000 IVUS-guided PCI procedures. The conversation explores how IVUS can distinguish high-risk from low-risk post-PCI hematomas, the imaging features associated with progression, and how these findings may help operators decide when additional stenting is necessary—and when careful observation may be the better strategy.
- Aug 4, 202635 min
Pediatric Heart Transplantation: When Priority Doesn't Match Urgency | JACC Baran
Pediatric heart transplantation is one of medicine's scarcest resources, where every allocation decision can mean the difference between life and death. But does the current system truly prioritize the children at greatest risk? Hosts Mitsuaki Sawano, MD, and Satoshi Shoji, MD welcome Kazunari Sasaki, MD (Stanford University) to discuss his JACC study, Status Exceptions and Misalignment of Medical Urgency in U.S. Pediatric Heart Transplantation. Using the national OPTN registry of more than 6,000 children awaiting heart transplantation, the study examines whether "status exceptions"—special requests to elevate transplant priority—accurately reflect medical urgency and whether the National Heart Review Board has improved the fairness of organ allocation. The episode explores why well-intentioned exception requests may unintentionally disadvantage the sickest children, how waiting-list mortality varies dramatically within the highest priority category, and why objective measures of medical urgency may be needed to improve equity in donor heart allocation. Dr. Sasaki also shares insights into the evolution of the U.S. transplant system, emerging innovations such as ex vivo heart perfusion, and how data-driven policy can shape the future of pediatric transplantation.
- Jul 28, 202635 min
PACs: Benign Bystanders or AF in Disguise? | JACC Baran
Premature atrial complexes (PACs) are among the most common arrhythmias encountered in daily practice and are often dismissed as benign. But are they truly harmless—or could some represent the earliest stage of atrial fibrillation (AF)? Hosts Mitsuaki Sawano, MD, and Hiroyuki Sato, MD welcome Satoshi Higuchi, MD (Tokyo Women's Medical University) to discuss his JACC: Clinical Electrophysiology study, Atrial Effective Refractory Periods in Patients With Frequent Premature Atrial Complexes: Implications for Atrial Fibrillation. Building on translational work from experimental models, the study compares atrial effective refractory periods (AERP) in patients with frequent PACs, paroxysmal AF, and persistent AF to better define the electrophysiologic substrate underlying these conditions. The episode explores how electrical remodeling differs between PACs and AF, why pulmonary vein AERP shortens before more diffuse atrial remodeling develops, and what these findings reveal about the progression from atrial ectopy to sustained arrhythmia. The discussion also examines the emerging concept of PAC-induced atrial cardiomyopathy, the challenge of distinguishing "benign" from potentially malignant PACs, and the future of risk stratification and preventive intervention before AF becomes established.
About JACC Global
Explore cardiovascular science from a global perspective with JACC Global. This podcast highlights original research, regional innovations, and urgent challenges in heart health across diverse healthcare settings worldwide.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from JACC Global in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's JACC Global daily summary?
It's a free AI-powered email that summarizes new episodes of JACC Global as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the JACC Global podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official JACC Global product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by American College of Cardiology.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does JACC Global release new episodes?
JACC Global publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does JACC Global cover?
JACC Global covers topics including Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting JACC Global summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.